Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Drug maker Zydus Lifesciences shares rise on partnership with MSN Laboratories for Riociguat tablets launch in the US. Zydus and MSN are the first companies to launch generic Riociguat, indicated for chronic thromboembolic pulmonary hypertension.
Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched the first generic version of Adempas (Riociguat tablets) in the US market. The launch includes Riociguat tablets in all five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg.